Supplementary Material

Synthesis and biological evaluation of coumarin-triazolyl ester conjugates as potential anticancer agents

Anarkul S. Kishkentayeva[1*], Mohammad Saleh Hamad[2], Mikhail A. Pokrovsky[2,3], Zhanar R. Shaimerdenova[1], Aigerim S. Adekenova[1], Gulnara K. Mambeterzina[1], Victor A. Savelyev[3], Andrey G. Pokrovsky[2], Elvira E. Shults[3*]

[1]School of Pharmacy, Medical University of Karaganda, Karaganda 100012, Kazakhstan

[2]Novosibirsk State University, Piragova Str., 1, 630090, Novosibirsk, Russian Federation

[3]N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russian Federation

* Correspondence: e-mail: anar_kish@mail.ru (ASK); e-mail: schultz@nioch.nsc.ru (EES)

Copies of ^{1}H and ^{13}C NMR for all new compounds, 2D NMR ^{1}H-^{1}H, ^{1}H-^{13}C for compounds **2a-i and 3**.

List of contents

Figure S1. ^{1}H NMR spectrum (400 MHz, $CDCl_3$) of compound **2a**
Figure S2. ^{13}C NMR spectrum (125 MHz, $CDCl_3$) of compound **2a**
Figure S3. ^{1}H NMR spectrum (300 MHz, $CDCl_3$) of compound **2b**
Figure S4. ^{13}C NMR spectrum (125 MHz, $CDCl_3$) of compound **2b**
Figure S5. ^{1}H NMR spectrum (500 MHz, $CDCl_3$) of compound **2c**
Figure S6. ^{13}C NMR spectrum (125 MHz, $CDCl_3$) of compound **2c**
Figure S7. ^{1}H NMR spectrum (300 MHz, $CDCl_3$) of compound **2d**
Figure S8. ^{1}H NMR spectrum (75 MHz, $CDCl_3$) of compound **2d**
Figure S9. ^{1}H NMR spectrum (400 MHz, $CDCl_3$) of compound **2e**
Figure S10. ^{13}C NMR spectrum (75 MHz, $CDCl_3$) of compound **2e**
Figure S11. ^{1}H NMR spectrum (400 MHz, $CDCl_3$) of compound **2f**
Figure S12. ^{13}C NMR spectrum (400 MHz, $CDCl_3$) of compound **2f**
Figure S13. ^{1}H NMR spectrum (400 MHz, DMSO-d_6) of compound **2g**
Figure S14. ^{13}C NMR spectrum (125 MHz, DMSO-d_6) of compound **2g**
Figure S15. ^{1}H NMR spectrum (300 MHz, $CDCl_3$) of compound **2h**
Figure S16. ^{13}C NMR spectrum (75 MHz, $CDCl_3$) of compound **2h**
Figure S17. ^{1}H NMR spectrum (300 MHz, $CDCl_3$) of compound **2i**
Figure S18. ^{13}C NMR spectrum (125 MHz, $CDCl_3$) of compound **2i**
Figure S19. ^{1}H NMR spectrum (300 MHz, $CDCl_3$) of compound **3**
Figure S20. ^{13}C NMR spectrum (75 MHz, $CDCl_3$) of compound **3**




Figure S1. ^{1}H NMR (400 MHz) spectrum of (1-benzyl-1*H*-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**2a**) recorded in $CDCl_3$.




Figure S2. ^{13}C NMR (125 MHz) spectrum of (1-benzyl-1*H*-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**2a**) recorded in $CDCl_3$.




Figure S3. ^{1}H NMR (300 MHz) spectrum of (1-phenyl-1*H*-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**2b**) recorded in $CDCl_3$.




Figure S4. ^{13}C NMR (125 MHz) spectrum of (1-phenyl-1*H*-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**2b**) recorded in $CDCl_3$.




Figure S5. ^{1}H NMR (500 MHz) spectrum of (1-(3,4-dimethylphenyl)-1*H*-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**2c**) recorded in $CDCl_3$.




Figure S6. ^{13}C NMR (125 MHz) spectrum of (1-(3,4-dimethylphenyl)-1*H*-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**2c**) recorded in $CDCl_3$.




Figure S7. ^{1}H NMR (300 MHz) spectrum of (1-(2-methoxycarbonyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**2d**) recorded in $CDCl_3$.




Figure S8. ^{13}C NMR (75 MHz) spectrum of (1-(2-methoxycarbonyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**2d**) recorded in $CDCl_3$.




Figure S9. ^{1}H NMR (400 MHz) spectrum of (1-(3-methoxycarbonyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**2e**) recorded in $CDCl_3$.




Figure S10. ^{13}C NMR (75 MHz) spectrum of (1-(3-methoxycarbonyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**2e**) recorded in $CDCl_3$.




Figure S11. ^{1}H NMR (400 MHz) spectrum of (1-(4-methoxycarbonyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**2f**) recorded in $CDCl_3$.




Figure S12. ^{13}C NMR (75 MHz) spectrum of (1-(4-methoxycarbonyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**2f**) recorded in $CDCl_3$.




Figure S13. ^{1}H NMR (400 MHz) spectrum of 4-(4-((2-oxo-2H-chromene-3-carbonyloxy) methyl)-1*H*-1,2,3-triazol-4-yl)benzoic acid (**2g**) recorded in DMSO-d$_6$.




Figure S14. ^{13}C NMR (125 MHz) spectrum of 4-(4-((2-oxo-2H-chromene-3-carbonyloxy) methyl)-1*H*-1,2,3-triazol-4-yl)benzoic acid (**2g**) recorded in DMSO-d$_6$.




Figure S15. ^{1}H NMR (300 MHz) spectrum of (1-(4-iodophenyl)-1*H*-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**2h**) recorded in $CDCl_3$.




Figure S16. ^{13}C NMR (75 MHz) spectrum of (1-(4-iodophenyl)-1*H*-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**2h**) recorded in $CDCl_3$.




Figure S17. ^{1}H NMR (300 MHz) spectrum of (1-butyl-1*H*-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**2i**) recorded in $CDCl_3$.




Figure S18. ^{13}C NMR (125 MHz) spectrum of (1-butyl-1*H*-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**2i**) recorded in $CDCl_3$.




Figure S19. ^{1}H NMR (300 MHz) spectrum of (1,1′-(pentane-1,5-diyl)bis(1*H*-1,2,3-triazol-4,1-diyl))bis(methylene) bis(2-oxo-2H-chromene-3-carboxylate) (3) recorded in $CDCl_3$.




Figure S20. ^{13}C NMR (75 MHz) spectrum of (1,1′-(pentane-1,5-diyl)bis(1*H*-1,2,3-triazol-4,1-diyl))bis(methylene) bis(2-oxo-2H-chromene-3-carboxylate) (3) recorded in $CDCl_3$.